At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including choroidal melanoma, diabetic macular edema, diabetic retinopathy, dry macular degeneration with geographic atrophy, retinal vein occlusion, wet macular degeneration, and uveitis.

We recently opened five new clinical trials:

Diabetic Macular Edema

  • Brunello (Dallas Main, Plano, Arlington, Fort Worth) — A Phase II/III study to evaluate intravitreal EYE103 compared with intravitreal ranibizumab in participants with diabetic macular edema (DME).

Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)

  • Archer 2 (Fort Worth, Dallas Main) — A study investigating intravitreal ANX007 in participants with geographic atrophy (GA).

Wet Macular Degeneration

  • Daybreak (Plano, Arlington, Fort Worth) — A Phase III study to evaluate intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration (AMD).
  • Lugano (Dallas Main, Plano) — A Phase III study of EYP-1901, a tyrosine kinase Inhibitor (TKI), compared to aflibercept in subjects with wet age-related macular degeneration (AMD).
  • Sanofi (Dallas Main) — A Phase I/II study to evaluate a one-time intravitreal SAR402663 in participants with wet age-related macular degeneration (AMD).

We currently have a total of 36 open studies. Click here to view our current, actively enrolling clinical trials.

For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.